Credit Suisse reviews script volume trends for the company’s key generic and specialty brands. With limited improvement in the final six weeks of FY19 the broker envisages downside risk to consensus forecasts.
Read MoreThe company has announced a significant deterioration in the performance of its generic products since the first half results because of increased competition and US$4m in one-off adverse items. The high-margin specialty brands revenue is also weaker than expected.
Read More
A rather severe confession time yesterday from generic drug group, Mayne Pharma with a warning of a big slide in revenue and profit and a possible write-down of asset values.
Read MoreMayne Pharma’s result was a big improvement on a weak previous period but was currency-assisted and disappointed nonetheless. Specialty brands stood out in revenue terms, the broker notes, but costs were elevated for various reasons.
Read MoreGeneric drugs group, Mayne Pharma saw its shares dip yesterday in the wake of yet another poor trading update.
Read MoreGeneric drug group, Mayne Pharma disappointed investors yesterday with the release of preliminary results for 2016-17 underwhelming investors.and sending the shares down nearly 10% to 81 cents.
Read MoreMayne’s investor day highlighted a plan to triple sales by 2021 through new product launches and M&A, which might have been exciting had the company not also revealed 10-15% quarterly price deflation in the generic portfolio acquired from Teva. Buyer consolidation was blamed.
Read MoreMayne Pharma Group’s (MYX) share price fell more than 10% to $1.20 yesterday and for that you can partly blame President Donald Trump and his erratic talk about controlling drug prices.
Read MoreManufacturer and distributor of pharmaceuticals, Mayne Pharma ((MYX)), is continuing its transformation and now has a portfolio of branded and generic medicines which have elevated it to a substantial player globally. The company has more development capability and directly distributes into the US. The market for generic medicines in the US is estimated to be at a US$60bn, and growing.
Read MoreDrug maker Mayne Pharma (MYX) is one of those rare stocks where investors expect much more from it in the coming year, than they saw in the year to June 30.
Read MoreMayne Pharma shares surged 28% yesterday after the company confirmed it had raised over half a billion in an institutional placement at $1.50 a share and rights issue as part of its dramatic move into the competitive US generic drugs market.
Read MoreMayne Pharma ‘ FY15 result came in in line with the broker after the turmoil of the first half, when the US Doryx distributor transitioned ownership, gave way to full Doryx margin reestablishment in the second half after Mayne acquired the Doryx brand.
Read More